Cited by 581Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Open access

van der Kant, Rik, Goldstein, Lawrence S. B., Ossenkoppele, Rik·2020·Nature reviews. Neuroscience

DOI 10.1038/s41583-019-0240-3

Open this paper in CoChat — free account

Abstract

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment can revert or arrest progression of this disease. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain. Genetic data, as well as autopsy and neuroimaging studies in patients with AD, indicate that Aβ plaque deposition precedes cortical tau pathology. Because Aβ accumulation has been considered the initial insult that drives both the accumulation of tau pathology and tau-mediated neurodegeneration in AD, the development of AD therapeutics has focused mostly on removing Aβ from the brain. However, striking preclinical evidence from AD mouse models and patient-derived human induced pluripotent stem cell models indicates that tau pathology can progress independently of Aβ accumulation and arises downstream of genetic risk factors for AD and aberrant metabolic pathways. This Review outlines novel insights from preclinical research that implicate apolipoprotein E, the endocytic system, cholesterol metabolism and microglial activation as Aβ-independent regulators of tau pathology. These factors are discussed in the context of emerging findings from clinical pathology, functional neuroimaging and other approaches in humans. Finally, we discuss the implications of these new insights for current Aβ-targeted strategies and highlight the emergence of novel therapeutic strategies that target processes upstream of both Aβ and tau.

Integrity signals

Registry

Crossref · 10.1038/s41583-019-0240-3

Cites

215 of 215 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979

Show all 216 references

Research works printed but not linked: 7

Kemp, A. Update on phase III clinical trials of lanabecestat for Alzheimer’s disease. AstraZeneca https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html (2018).
Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). This large meta-analysis provides prevalence estimates of Aβ positivity in cognitively normal persons and patients with MCI. · DOI · Paper page
Cho, H. et al. Progressive tau accumulation in Alzheimer’s disease: two-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019). · DOI · Paper page
Hutter-Paier, B. et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44, 227–238 (2004). This study shows that cholesteryl esters can drive accumulation of Aβ pathology in AD mice and that ACAT inhibitors have potential utility in the treatment of AD. · DOI · Paper page
Mecozzi, V. J. et al. Pharmacological chaperones stabilize retromer to limit APP processing. Nat. Chem. Biol. 10, 443–449 (2014). This revolutionary biochemical study uses in silico screening to discover a small molecule that is capable of stabilizing the retromer complex. · DOI · Paper page
Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523–527 (2017). This elegant mouse study shows that the ApoE*4 genotype affects tau pathology in the absence of Aβ pathology. · DOI · Paper page
Santacruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005). This is the first study to show that reducing tau expression in tau transgenic mice can rescue neuronal loss and behavioural deficits, even when extensive neurofibrillary tangles are already present. · DOI · Paper page

Sorted by citations

Items 501–581 of 581

The effect of reminder focused positive psychiatry suicide safety (RFPP-S) on COVID-19 related PTSD with PGD
Ahmadi, N., Steinberg, A. M., & Pynoos, R. S. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.08.012
Editorial: Degenerative and cognitive diseases
Giliberto, L. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001037
Alzheimer’s disease as a syndrome of overloaded amyloidic synaptic tagging in memory networksPreprint
Murphy, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/7gsaz
Three-dimensional structure of proteins and disorders of protein misfolding
Ha, C. E., & Bhagavan, N. V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88541-6.00033-8
A Computational approach to uncover the missense mutations in candidate genes of late-onset Alzheimer’s diseasePreprint
Mubeen, H., Masood, A., Zafar, A., Khan, Z. Q., Khan, M. Q., Nisa, A. U., & Naveed, Z. A. (2022) · Research Square · doi:10.21203/rs.3.rs-2060964/v1
Advantages and limitations of hiPSC-derived neurons for the study of neurodegeneration
Mishra, S., Deursen, C. V., Robert, A., van der Kant, R., & Young, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822277-5.00016-x
Neurodegeneracy
Tazeen, S., & Ibrahim, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109597
Amyloid Precursor Protein and Tau Peptides Linked Together Ameliorate Loss of Cognition in an Alzheimer’s Disease Animal Model
Maron, R., Vinik, Y., Tsoory, M., Wilchek, M., & Arnon, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512527
Lipid metabolism in neurodegenerative diseases
Bogie, J. F. J., Guns, J., & Vanherle, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00008-5
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
Wang, Y., Pascoal, T. A., Therriault, J., Kang, M.-S., Benedet, A. L., Savard, M., Tissot, C., Lussier, F. Z., Arias, J. F., Mathotaarachchi, S. S., et al. (2023) · doi:10.32920/24438049
Differential Associations of APOEɛ2 and APOEɛ4 Genotypes with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in Individuals Without Dementia
Zhao, B., Initiative, A. D. N., Ou, Y., Zhang, X.-Y., Fu, Y., & Tan, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230761
Altered T cell reactivity to β-amyloid-related antigens in early Alzheimer’s diseasePreprint
Rickenbach, C., Mallone, A., Häusle, L., Frei, L., Seiter, S., Sparano, C., Kirabali, T., Blennow, K., Zetterberg, H., Ferretti, M. T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.04.597424
Upregulation of serum miR 155 and miR 30c as a Potential Biomarker for Alzheimer’s DiseasePreprint
Kafshdooz, T., Farajnia, S., Sharifi, R., Najmi, S., & Pourseif, M. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4495031/v1
Relationship Between Dyslipidemia and Alzheimer’s Disease
Bolayırlı, M., & Kücür, M. (2024) · doi:10.69860/nobel.9786053359166.12
An Inflammation Centered Perspective to the Mechanisms and Interactions Related to Vascular Cognitive ImpairmentPreprint
Zeylan, M. E., Senyuz, S., Keskin, Ö., & Gürsoy, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.19.613013
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Joodaki, M., Shirazi, M. M., & Hosseini, N. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.3.219
Systemic exposure to COVID-19 virus-like particles modulates firing patterns of cortical neurons in the living mouse brainPreprint
Das, A., Icardi, J., Borovicka, J. A., Holden, S. J., Harrison, H. F., Hirsch, A. J., Raber, J., & Dana, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.26.625543
Perspective on Tau Hypothesis in Alzheimer’s Disease: Traversing the Therapeutic Potential of Flavonoids
kumari, D., Choudhary, M., Bamrah, P. K., Malan, A., & nitesh, N. (2025) · The Natural Products Journal · doi:10.2174/0122103155343062250130055607
Associations of varicose veins with cerebrospinal fluid biomarkers of Alzheimer’s disease pathologies in adults without dementia: the CABLE study
Liu, M., Ma, L., Li, Q., Huang, L., Hu, H., Tan, L., & Hu, H. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1502154
Melatonin ameliorates tauopathy and ferroptosis in P301S Tau transgenic mice
Jia, M., Wang, L., Guo, S.-Q., Liang, X.-T., Liu, X., Guo, S.-J., Wang, T., Zhong, M., Gao, H., & Guo, C. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.40
Differential effects of neurodegenerative disorders on verbal creative idea generation and its cognitive cornerstonesPreprint
Chan, M. M. Y., O’Sullivan, J. D., Adam, R. J., Mosley, P. E., Breakspear, M. J., & Robinson, G. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.22.650134
Differences in Glucose Metabolism Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Longitudinal Study From SILCODE
Wei, M., Wang, L., Yu, X., Hu, W., Wang, M., Zhang, Q., Guo, T., Zhong, J., Li, C., Jiang, J., et al. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70264
Sound-evoked auditory neurophysiological signals are a window into prodromal functional differences in a preclinical model of Alzheimer’s disease
Aydın, A. G., Manoj, P. K., Ramadan, F., Rajan, S., Youssef, E., Torres, E. B., & Bieszczad, K. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-51854-8
Alzheimer’s Disease: Pathophysiological and Therapeutical Insights
Tyagi, K., Sarup, P., & Malik, J. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_1 · Cited by 1
Investigation of three flavonoids as potent tau aggregation inhibitors and In vivo demonstration of myricetin
Benin, B. M., Hillyer, T., Csubak, B. A., Aguirre, N., Crish, S. D., Kang, C., & Shin, W. S. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100449
Additional file 1 of Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614732
Additional file 1 of APOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., & Mormino, E. C. (2023) · Figshare · doi:10.6084/m9.figshare.22608413
Additional file 5 of Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614744
Additional file 2 of PDZD8-deficient mice manifest behavioral abnormalities related to emotion, cognition, and adaptation due to dyslipidemia in the brain
Kurihara, Y., Mitsunari, K., Mukae, N., Shoji, H., Miyakawa, T., & Shirane, M. (2024) · Figshare · doi:10.6084/m9.figshare.26562910
Additional file 1 of A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
Gao, Y., Wang, Y., Lei, H., Xu, Z., Li, S., Yu, H., Xie, J., Zhang, Z., Liu, G., Zhang, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24546913
Additional file 6 of Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b
Hosseini-Gerami, L., Ficulle, E., Humphryes-Kirilov, N., Airey, D. C., Scherschel, J., Kananathan, S., Eastwood, B. J., Bose, S., Collier, D. A., Laing, E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22618886
Additional file 1 of Regional cerebral tau predicts decline in everyday functioning across the Alzheimer’s disease spectrum
Dubbelman, M. A., Mimmack, K. J., Sprague, E. H., Amariglio, R. E., Vannini, P., & Marshall, G. A. (2023) · Figshare · doi:10.6084/m9.figshare.23632654
Investigating the hidden mechanism underlying the tau interaction by methylene bluePreprint
Seo, D.-H., Huh, Y. H., Yoo, H.-J., Cho, K., Cheong, H.-K., Kim, E.-H., Choi, J., Kim, H. N., Bang, J., Lim, J.-S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2935088/v1 · Cited by 1
Additional file 4 of Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614741
Additional file 2 of Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614735
Additional file 1 of Associations of the cerebrospinal fluid hepatocyte growth factor with Alzheimer’s disease pathology and cognitive function
Zhao, L.-J., Wang, Z.-T., Ma, Y.-H., Zhang, W., Dong, Q., Yu, J.-T., & Tan, L. (2021) · Figshare · doi:10.6084/m9.figshare.16755740
Additional file 1 of PDZD8-deficient mice manifest behavioral abnormalities related to emotion, cognition, and adaptation due to dyslipidemia in the brain
Kurihara, Y., Mitsunari, K., Mukae, N., Shoji, H., Miyakawa, T., & Shirane, M. (2024) · Figshare · doi:10.6084/m9.figshare.26562907
Additional file 3 of Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status
Bun, S., Ito, D., Tezuka, T., Kubota, M., Ueda, R., Takahata, K., Moriguchi, S., Kurose, S., Momota, Y., Suzuki, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26614738
FAM84B facilitates tau propagation via RYR3-mediated exocytosis in response to neuroinflammationPreprint
Yoon, G., Park, H., Park, J. E., Kam, M. K., Kim, J.-H., Kim, E., Park, S.-H., Kim, H., Johnson, G. V. W., Choi, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.28.696549
Prospect in Alzheimer’s disease integrative therapy targeting both amyloid-beta and tau
Zhang, W., Zhou, Y., Chen, J., Pérez, M., Claure, X., & Leblanc, R. M. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00916 · Cited by 1
Organizational principles of the cerebral cortex predict symptoms progression in the Alzheimer’s disease spectrum
Menardi, A., Rocca, B. L., Saglam, C., Alberti, F., Cecchin, D., Venneri, A., Cagnin, A., & Vallesi, A. (2026) · NeuroImage · doi:10.1016/j.neuroimage.2026.121696 · Cited by 1
Timed 360° turn test in people with Alzheimer′s disease: a reliability and validity study
Söke, F., Ataoğlu, E. E., Gülşen, Ç., Yorulmaz, D. K., Gulfirat, F. N., & Tokçaer, A. B. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04258-y
Phosphorylated peptide Tau-pT181 induced tau aggregation and cognitive dysfunction
Luo, Y., Wu, G., Liu, Y., Yin, A., Huang, Z., Wang, J., Liu, R., Wang, X., & Gui, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251413719
Sleep duration, depression, and cognitive function among older adults in China: A longitudinal cohort study
Jiang, J., Zhou, J., Li, Y., & Duan, X. (2026) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2026.103450
Computational prospection of functional peptides from kefir microbiota with multitarget potential in Alzheimer’s disease
Fonseca, S. H. P., Santos, A. C. C., Silva, M. H., Malta, S. M., & Ueira-Vieira, C. (2026) · International Journal of Food Science & Technology · doi:10.1093/ijfood/vvag033
A unique compound 3c targets GSK-3β and metal ion, interferes with tau and metal dyshomeostasis, promotes neurite outgrowth, decreases Aβ accumulation and ABTS•+, and enhances zebrafish motility
Zhang, J., Li, Y., Li, Y.-P., Xun, Q., Ma, Y., & Shi, X.-L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109760
Implication de nouvelles cibles microgliales, Cst7 et Clec7a/Dectin-1, dans le développement et la progression de la maladie d'Alzheimer
Hemonnot-Girard, A.-L. (2021) · theses.fr (ABES) · doi:10.70675/9c8a4775zd774z494ez9bbazf7566faefa8f
Étude de la forme sporadique de la maladie d'Alzheimer à partir de modèles in vivo et de neurones humains reprogrammés
Thiberge, C. (2023) · theses.fr (ABES) · doi:10.70675/de2fa338z7aecz4991za94eze8b7694a0d22
Using β-strand and β-hairpin peptidomimetics induced by constrained amino acids to modulate the aggregation of the microtubule associated protein Tau : design, synthesis and evaluation
Lorenzo, D. D. (2023) · theses.fr (ABES) · doi:10.70675/0bdac871z5f25z4b5az9467z96a6d16ffb34
Hétérogénéité et régulation des astrocytes dans la maladie d'Alzheimer : vers des interventions ciblées sur les voies JAK2-STAT3 et NF-kB
Poulot-Becq-Giraudon, Y. (2024) · theses.fr (ABES) · doi:10.70675/0d7a8b92z8393z4d76z82a8z87efe0790346
Neuroimagerie des altérations du lobe temporal médian : avancées pour la compréhension, l'évaluation et la prévention de la maladie d'Alzheimer 22017004
Chauveau, L. (2024) · theses.fr (ABES) · doi:10.70675/21081e29ze9c3z431azb7a5zb77aaaddfc26
Association of inflammation-related plasma proteins with vascular cognitive burden and Alzheimer's disease: A multi-method study
Ye, Z., Teng, B., Wang, S., Zhu, J., Chen, J., Zhang, B., Cai, H., Wei, R., Li, B., Xie, X., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261443713
Blood ATX(N) Biomarkers and Cognitive Dysfunction in Severe Mental Illnesses
Crescenti, D., Petracci, I., Cesareni, A., Binetti, G. G., Borroni, B., & Ghidoni, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104260
Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease
Xu, X., Li, L., Huang, W., Yang, Y., Li, X., Wang, P., Zhao, M., Zhang, H., & Yuan, C. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100619
Brain protein burden is related to intravoxel incoherent motion: PET-MR imaging study
Hemachandra, D., Zheng, K., Lorkiewicz, S. A., Winer, J. R., Vossler, H. A., Davidzon, G., Mormino, E. C., Schulte, T., Poston, K. L., & Müller‐Oehring, E. M. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1841093
Peptide vaccination for Alzheimer's disease: Immunological foundations, therapeutic potential, and translational barriers
Chen, H., Lin, Y. Y., Kang, D., & Zhao, T. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261462546
Higher baseline CSF cortisol is associated with adverse 24-month tau-related, neuroimaging, and cognitive outcomes across the Alzheimer’s disease continuum
Alreshidi, N. F., Alghamdi, A. A., Almasoudi, K. S., Mirza, I. M., Abduljawad, S. A., Zakaria, S. S., Alharbi, S. S., & Initiative, A. D. N. (2026) · European Geriatric Medicine · doi:10.1007/s41999-026-01562-3
Classification of tau status with machine learning models in amyloid‐positive cohorts
Lin, Y., Chiu, S.-C., Massey, R., Fang, Y.-H. D., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71683 · Cited by 1
Exploring the Step-Growth Polymerization Reaction Kinetics and Polydispersity of Amyloid Beta Aggregation
Majid, A., & Garg, S. (2026) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.6c02494
Emerging neuroprotective mechanisms and therapeutic potential of natural polysaccharides in Alzheimer's disease
Muhammad, N., Ai, R., Yang, L., Cui, Y., Wang, L., Weng, S., Wang, Y., Kakar, M. U., Khan, S., Ahmad, S., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1877358 · Cited by 1
Small nucleolar RNAs: Emerging therapeutic and diagnostic frontiers in Alzheimer’s disease
Sharma, T., Sharma, P., Bashir, B., Singh, S. K., & Vishwas, S. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104771
Title: Gene expression, neuroinflammation, and neural plasticity in type 2 diabetes: Translational insights from exercise and cognitive modulation
Diniz, C. G., Bento-Torres, N. V. O., da Costa, E. R., Magalhães, N. G. D. M., de Melo, M. A. D., Pereira, P. D. C., Carvalho, J. P. R., Magno, G. M., Bento‐Torres, J., Sosthenes, M. C. K., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106922
A vascular component to the selective vulnerability of the medial temporal lobe to tau pathology
Doyon, V., Janelle, F., Sean, M., Vanderweyen, D., Cote, S. R., Huck, J., Tétreault, P., Lepage, J., Gutierrez, J., Bocti, C., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag301
Early Hetero-Oligomerization of Tau Fragments Redirects Cofactor-Free Tau Assembly and Fibril Morphology
Safoah, H. A., Hirschbeck, S. S., Chen, J., Domingo, N., Sogolovsky-Bard, I., Sams, A., Harish, A., Melkonian, M. J., Cantrell, K. L., Bar‐Yosef, D. L., et al. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c05345
Near-Infrared Imaging of Senescence-Associated β-Galactosidase Enables Discovery of a Glycerol-3-Phosphate Dehydrogenase 2-Regulated Neuroprotective Pathway in Alzheimer’s Disease
Xu, C., Liang, H., Chen, Y., Wang, X., Selvan, G. T., Wang, K., Zhu, Q., Xing, Y., Dou, K., Yu, F., et al. (2026) · ACS Sensors · doi:10.1021/acssensors.6c02748
Tau deposition patterns within the medial temporal lobe follow the connectivity of the entorhinal and perirhinal cortex – a combined post-mortem and 7T fMRI studyPreprint
de Bruin, H., Przygodda, X., Wisse, L. E. M., Ravikumar, S., Düzel, E., Pijnenburg, Y. A. L., Yushkevich, P. A., Groot, C., Berron, D., Franzmeier, N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10581799/v1
Self-citation
Virobiome-mediated regulation of microbiota–gut–brain axis signaling and neuroimmune homeostasis
Afkhamian, A., Natanzi, A. S., Jafaridarabjerdi, M., Aghaei, S., Haghjou, A., Shafiei, M., Bashkandi, A. H., Shahraki, S., Reiter, R. J., Kashani, H. H., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03067-9
Nanoconjugation of chalcone derivatives and carbon nitride dots for the inhibition of tau aggregation
Zhang, W., Smith, N., Véliz, E. A., Zhao, B., Kandel, N., Joji, A., Chen, J., Ferreira, B. C. L. B., Pérez, M., Claure, X., et al. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.116175
Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis
Ciaccio, M., & Agnello, L. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70533
Altered Resting State Hippocampal Connectivity Associated With Amyloid and Tau in Older Adults Without Dementia From a Population-Based Cohort Study
Roberts, A., Andreescu, C., Cohen, A., Nadkarni, N. K., Minhas, D. S., Laymon, C. M., Lopresti, B. J., Snitz, B. E., & Karim, H. T. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.09.003
Peroxisomes in Alzheimer’s disease: emerging mechanistic insights and therapeutic opportunities
Liu, T., Liu, Y., Zhang, Y., Wang, J., Ren, Y., Fu, S., Han, L., 蒋鹏成, Chen, J., Li, Y., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1960320
From bench to beside: luteolin's therapeutic promise in neurological disorders
Zhu, W., Yuan, N., Tang, M., She, K., Chen, M., Huang, M., Feng, R., Ma, Q., & Chen, J. (2026) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(26)61211-3
Early assessment of cognitive decline and dementia risk in Parkinson's disease: Prevention and implications for healthcare professionals
Fares, A. (2026) · Advances in Clinical Neuroscience & Rehabilitation · doi:10.47795/lxkr6734
Pharmacologically induced models of dementia: Еxperimental approaches and applications
Ahmedova, M., & Gancheva, S. (2026) · Scripta Scientifica Medica · doi:10.14748/91nkeb14
Alzheimer’s disease neuropathological characterization of the dog brain and relationship to biofluid biomarkers and cognitive function
Alsulami, A., Bogdani, M., MacLean, E. L., Keene, C. D., McGrath, S., Akey, J. M., Benton, B., Borenstein, E., Castelhano, M. G., Coleman, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00141-4
Global and regional amyloid-β in explaining APOE-ε4 and sex associations with medial temporal tau: a neuropathology study
Salvadó, G., Groot, C., Wisse, L. E. M., Vogel, J. W., Beach, T. G., Serrano, G. E., Reiman, E. M., Schneider, J. A., Bennett, D. A., Ossenkoppele, R., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03095-2
Self-citation
Beyond the brain-centric view: A systems physiology framework for exercise-induced neuroprotection in Alzheimer's disease
Changjian, W., Furui, W., Yanyu, F., Yü, Y., & Wei, J. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.116058
Molecular Pathogenesis of Cerebral Amyloid Angiopathy in Alzheimer’s Disease: The Role of the Central Fibrinolytic Cascade at the Neurovascular Unit
Kumar, S., Paswan, S. K., Verma, P., Chaturvedi, S., Vishwakarma, V. K., & Yadav, H. N. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06263-3
Neurotrophic regulation of lipid metabolism in Alzheimer's disease: Mechanisms and therapeutic implications
Fan, D., Zhai, W., Zhang, Q., Li, J., Wang, Y., & Sun, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261499707
BindingDB Entry 50022831: A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD).
BindingDB (2026) · UC San Diego · doi:10.7270/q2c53rpz
Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cellsPreprint
Meng, W., Zhang, J., Zhang, S., Shi, Y., & Wang, H. (2026) · Research Square · doi:10.21203/rs.3.rs-11212419/v1

Authors: van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R.
Affiliations: University of California San Diego (US)
Lund University (SE)
ORCID: van der Kant, Rik
Goldstein, Lawrence S. B.
Ossenkoppele, Rik
Venue: Nature reviews. Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2019-11-28
Volume: 21
Issue: 1
Pages: 21-35
ISSN: 1471-003X (ISSN-L)
1471-0048
DOI: 10.1038/s41583-019-0240-3
OpenAlex: W2989855650
Cited by: 580
References: 216
Citations by year: 2026: 57 · 2025: 89 · 2024: 93 · 2023: 89 · 2022: 95 · 2021: 95 · 2020: 61
FWCI: 7.39
Type: journal article
Language: en
Open access: green
research.vu.nl
Licence: other-oa
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Neuroscience (publishedVersion)
PubMed (publishedVersion)
VU Research Portal (publishedVersion, other-oa)
Lund University Publications (Lund University) (submittedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Institute on Aging (RF1AG048083)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, tau pathology, amyloid-beta, apolipoprotein E, cholesterol metabolism, microglial activation, induced pluripotent stem cell models, mouse model
MeSH terms: Alzheimer Disease, Animals, Apolipoproteins E, Cholesterol, Endocytosis, Humans, Amyloid beta-Peptides, tau Proteins, Microglia, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks